Do Traders Think Lexaria Bioscience Corp (LEXX) Can Keep Climbing Tuesday?

Lexaria Bioscience Corp (LEXX) stock has gained 4.63% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Lexaria Bioscience Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LEXX!

See Full LEXX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With LEXX Stock Today?

Lexaria Bioscience Corp (LEXX) stock has gained 2.34% while the S&P 500 is lower by -0.61% as of 1:36 PM on Tuesday, Nov 9. LEXX has gained $0.13 from the previous closing price of $6.40 on volume of 32,650 shares. Over the past year the S&P 500 has gained 31.59% while LEXX has gained 11.39%. LEXX lost -$0.87 per share in the over the last 12 months.

More About Lexaria Bioscience Corp

Lexaria Bioscience Corp's drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream. DehydraTECH increases absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to minutes, and masks unwanted tastes. With 18 patents granted for use with nicotine, NSAIDs and cannabinoids; and over 60 patents pending for antiviral drugs; hormones, PDE5 inhibitors, and more, our areas of focus include heart disease, viruses, Parkinsons and more. Click Here to get the full Stock Report for Lexaria Bioscience Corp stock.